Cardiff Oncology (CRDF) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $0.97, +0.00% vs the prior close of $0.97.
- Volume 453.80K shares, 0.6x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CRDF ends flat (+0.0%) to $0.97, 4 down days in a row. Closed at $0.97, +0.00% vs the prior close of $0.97. Day range $0.95–$1.00, opened at $0.95.
CRDF daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — CRDF ends flat (+0.0%) to $0.97, 4 down days in a row
- Closed at $0.97, +0.00% vs the prior close of $0.97. Day range $0.95–$1.00, opened at $0.95.
- Volume was 453.80K shares, 0.6x its 50-day average of 709.96K.
- Price is -11.3% vs its 50-day average ($1.09) and -37.4% vs its 200-day average ($1.55).
- 52-week range $0.76–$3.31; today's close sits at 8% of that range, 70.7% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — CRDF slides 4.0% to $0.97, a 1-month low, 3 down days in a row
- Closed at $0.97, -3.96% vs the prior close of $1.01. Day range $0.96–$1.06, opened at $1.06.
- Volume was 412.90K shares, 0.6x its 50-day average of 714.64K — lighter than usual.
- Price is -11.3% vs its 50-day average ($1.09) and -37.8% vs its 200-day average ($1.56).
- 52-week range $0.76–$3.31; today's close sits at 8% of that range, 70.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CRDF dips 2.9% to $1.01, a 1-month low
- Closed at $1.01, -2.88% vs the prior close of $1.04. Day range $1.00–$1.05, opened at $1.04.
- Volume was 504.80K shares, 0.7x its 50-day average of 730.24K.
- Price is -7.6% vs its 50-day average ($1.09) and -35.6% vs its 200-day average ($1.57).
- 52-week range $0.76–$3.31; today's close sits at 10% of that range, 69.5% below the 52-week high.
Oct 12, 2026 — CRDF slides 3.7% to $1.04, a 1-month low
- Closed at $1.04, -3.70% vs the prior close of $1.08. Day range $1.04–$1.08, opened at $1.08.
- Volume was 377.20K shares, 0.5x its 50-day average of 734.34K — lighter than usual.
- Price is -4.7% vs its 50-day average ($1.09) and -34.2% vs its 200-day average ($1.58).
- 52-week range $0.76–$3.31; today's close sits at 11% of that range, 68.6% below the 52-week high.
Oct 9, 2026 — CRDF rises 1.9% to $1.08
- Closed at $1.08, +1.89% vs the prior close of $1.06. Day range $1.06–$1.11, opened at $1.06.
- Volume was 297.40K shares, 0.4x its 50-day average of 756.11K — lighter than usual.
- Price is -0.7% vs its 50-day average ($1.09) and -32.1% vs its 200-day average ($1.59).
- 52-week range $0.76–$3.31; today's close sits at 13% of that range, 67.4% below the 52-week high.
Oct 8, 2026 — CRDF dips 2.8% to $1.06
- Closed at $1.06, -2.75% vs the prior close of $1.09. Day range $1.05–$1.08, opened at $1.07.
- Volume was 541.00K shares, 0.7x its 50-day average of 769.33K.
- Price is -2.1% vs its 50-day average ($1.08) and -33.7% vs its 200-day average ($1.60).
- 52-week range $0.76–$3.31; today's close sits at 12% of that range, 68.0% below the 52-week high.
Oct 7, 2026 — CRDF rises 1.9% to $1.09
- Closed at $1.09, +1.87% vs the prior close of $1.07. Day range $1.07–$1.13, opened at $1.07.
- Volume was 457.50K shares, 0.6x its 50-day average of 782.56K — lighter than usual.
- Price is +1.1% vs its 50-day average ($1.08) and -32.1% vs its 200-day average ($1.61).
- 52-week range $0.76–$3.31; today's close sits at 13% of that range, 67.1% below the 52-week high.
Oct 6, 2026 — CRDF slides 6.1% to $1.07
- Closed at $1.07, -6.14% vs the prior close of $1.14. Day range $1.06–$1.16, opened at $1.15.
- Volume was 384.20K shares, 0.5x its 50-day average of 792.11K — lighter than usual.
- Price is -0.3% vs its 50-day average ($1.07) and -33.7% vs its 200-day average ($1.61).
- 52-week range $0.76–$3.31; today's close sits at 12% of that range, 67.7% below the 52-week high.
Oct 5, 2026 — CRDF rises 1.8% to $1.14
- Closed at $1.14, +1.79% vs the prior close of $1.12. Day range $1.09–$1.15, opened at $1.10.
- Volume was 451.90K shares, 0.6x its 50-day average of 807.09K — lighter than usual.
- Price is +6.7% vs its 50-day average ($1.07) and -29.6% vs its 200-day average ($1.62).
- 52-week range $0.76–$3.31; today's close sits at 15% of that range, 65.6% below the 52-week high.
Oct 2, 2026 — CRDF slides 5.1% to $1.12
- Closed at $1.12, -5.08% vs the prior close of $1.18. Day range $1.11–$1.21, opened at $1.21.
- Volume was 628.30K shares, 0.8x its 50-day average of 807.62K.
- Price is +5.5% vs its 50-day average ($1.06) and -31.1% vs its 200-day average ($1.63).
- 52-week range $0.76–$3.31; today's close sits at 14% of that range, 66.2% below the 52-week high.
CRDF latest news & SEC filings
Every SEC filing by or about CRDF in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 26, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Aug 26, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 14, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $104.00K (prior year $121.00K) (-14.0% vs Jun 30, 2025)
- Net income: -$9.23M (prior year -$13.94M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.14 (prior year -$0.21) (loss narrowed vs Jun 30, 2025)
Jul 27, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 21, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Jul 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Pace Gary W bought 687,285 shares at $1.46 (≈$1.00M) on Jul 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mohindru Mani bought 34,364 shares at $1.46 (≈$50.17K) on Jul 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Jul 16, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mohindru Mani bought 24,703 shares at $1.21 (≈$29.89K) on Jun 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Pace Gary W bought 30,000 shares at $1.22 (≈$36.60K) on Jun 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade CRDF
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Nov 6, 2025, Jul 29, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.85% (largest 6.1%).
- Liquidity: about 479.23K shares (≈$464.85K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.97 vs a range of $0.76–$3.31 (8% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: Gary W Pace bought 687,285 shares on Jul 14, 2026.
- Latest filings: 8-K Sep 14, 2026; 8-K Aug 11, 2026; 10-Q Aug 11, 2026.
- Share count: 77.80M shares outstanding (Aug 6, 2026), +16.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
CRDF market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 0.95 | 1.00 | 0.95 | 0.97 | 453.80K |
| Oct 14, 2026 | 1.06 | 1.06 | 0.96 | 0.97 | 412.90K |
| Oct 13, 2026 | 1.04 | 1.05 | 1.00 | 1.01 | 504.80K |
| Oct 12, 2026 | 1.08 | 1.08 | 1.04 | 1.04 | 377.20K |
| Oct 9, 2026 | 1.06 | 1.11 | 1.06 | 1.08 | 297.40K |
| Oct 8, 2026 | 1.07 | 1.08 | 1.05 | 1.06 | 541.00K |
| Oct 7, 2026 | 1.07 | 1.13 | 1.07 | 1.09 | 457.50K |
| Oct 6, 2026 | 1.15 | 1.16 | 1.06 | 1.07 | 384.20K |
| Oct 5, 2026 | 1.10 | 1.15 | 1.09 | 1.14 | 451.90K |
| Oct 2, 2026 | 1.21 | 1.21 | 1.11 | 1.12 | 628.30K |
| Oct 1, 2026 | 1.22 | 1.22 | 1.16 | 1.18 | 298.40K |
| Sep 30, 2026 | 1.17 | 1.25 | 1.17 | 1.21 | 564.60K |
| Sep 29, 2026 | 1.19 | 1.24 | 1.16 | 1.17 | 353.00K |
| Sep 28, 2026 | 1.23 | 1.23 | 1.19 | 1.20 | 377.40K |
| Sep 25, 2026 | 1.30 | 1.30 | 1.23 | 1.24 | 563.40K |
| Sep 24, 2026 | 1.30 | 1.32 | 1.25 | 1.28 | 596.30K |
| Sep 23, 2026 | 1.32 | 1.34 | 1.28 | 1.31 | 590.10K |
| Sep 22, 2026 | 1.37 | 1.39 | 1.33 | 1.33 | 518.50K |
| Sep 21, 2026 | 1.39 | 1.41 | 1.36 | 1.37 | 476.00K |
| Sep 18, 2026 | 1.29 | 1.39 | 1.29 | 1.37 | 737.80K |
About Cardiff Oncology
Cardiff Oncology (CRDF) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1213037.
CRDF board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| James O Armitage | Director | Jun 15, 2026 |
| Rodney S Markin | Director | Jun 15, 2026 |
| Mani Mohindru | Chief Executive Officer | Jul 16, 2026 |
| Gary W Pace | Director | Jul 16, 2026 |
| Renee P Tannenbaum | Director | Jun 15, 2026 |
| Lale White | Director | Jun 15, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ajay Aggarwal | Chief Operating Officer | Apr 28, 2026 |
| Brigitte Ute Lindsay | Chief Accounting Officer | Feb 18, 2026 |
| Mani Mohindru | Chief Executive Officer | Jul 16, 2026 |
| Joshua B Muntner | Chief Financial Officer | Apr 16, 2026 |
| Tod Smeal | Chief Scientific Officer | Apr 16, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 14, 2026 | Gary W Pace | Buy | 687,285 | $1.46 |
| Jul 14, 2026 | Mani Mohindru | Buy | 34,364 | $1.46 |
| Jun 18, 2026 | Mani Mohindru | Buy | 24,703 | $1.21 |
| Jun 18, 2026 | Gary W Pace | Buy | 30,000 | $1.22 |
CRDF financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $593.00K | $-45.85M | -0.69 | $-37.92M |
| Dec 31, 2024 | $683.00K | $-45.43M | -0.95 | $-37.69M |
| Dec 31, 2023 | $488.00K | $-41.44M | -0.93 | $-30.89M |
| Dec 31, 2022 | $386.00K | $-38.70M | -0.89 | $-33.82M |
| Dec 31, 2021 | $359.00K | $-28.29M | -0.73 | $-23.04M |
Latest balance sheet: total assets $37.33M, total liabilities $10.80M, cash $9.20M (as of Jun 30, 2026).
CRDF earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $1.05 |
| May 14, 2026 | 8-K Item 2.02 (results) | $1.73 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $2.25 |
| Jul 29, 2025 | 8-K Item 2.02 (results) | $3.31 |
| May 8, 2025 | 8-K Item 2.02 (results) | $2.63 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $4.06 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $4.09 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
| Aug 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on CRDF
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.